Occurrence for Pre-eclampsia or SGA [ Time Frame: During pregnancy and until 72h after delivery ] [ Designated as safety issue: No ]

Pre-eclampsia is defined as hypertension (systolic blood pressure 140mmHg or greater or a diastolic blood pressure 90mmHg or greater on at least 2 occasions 4 hour or 1 week apart) accompanied by proteinuria (more or equal to 0.5g/day or 1 dipstick of ++ or more). SGA is defined as birth weight below the 10th centile for gestational age at birth according to the national birthweight distribution of the french population (INSERM)

Secondary Outcome Measures:

Early onset pre-eclampsia [ Time Frame: During pregnancy and until 72h after delivery ] [ Designated as safety issue: No ]

Early onset pre-eclampsia is defined as pre)eclampsia occurring before 32 completed gestational weeks.

Severe pre-eclampsia [ Time Frame: During pregnancy and until 72h after delivery ] [ Designated as safety issue: No ]

Pre-eclampsia (PE) and intrauterine growth restriction (IUGR) are known as major factors in perinatal morbidity and mortality. Routine antenatal care is focused on the detection of women at increased risk to apply this population a program of careful monitoring and appropriate intervention.

Uterine artery Doppler during anomaly scan at 12 to 14 weeks in selected women at increased risk, has proved to be accurate to detect those who will develop PE or IUGR during the second half of pregnancy.

A variety of angiogenic proteins have been studied as potential markers for pre-eclampsia. Among these protein Plgf and sflt-1 have respectively demonstrated higher and lower levels in pregnant women who will subsequently develop pre-eclampsia.

Our study is aimed to evaluate the performance of serum Plgf and sflt-1 measurement in association with uterine artery Doppler as a screening for placental insufficiency.

Eligibility

Ages Eligible for Study:

18 Years and older

Genders Eligible for Study:

Female

Accepts Healthy Volunteers:

No

Sampling Method:

Non-Probability Sample

Study Population

Pregnant between 12 and 14 weeks

Criteria

Inclusion Criteria:

Chronic hypertension under medication

Insulin or not insulin dependant preexisting diabetes

Previous history of pre-eclampsia

Previous history of unexplained stillbirth

Previous history of placental abruption

Previous history of SGA (< 10th centile)

History of pre-eclampsia or chronic hypertension before 45 years in the mother or a sister

History of vascular pathology before 50 years in the father

Obesity (BMI>26)

Nulliparous after 38 years

Assisted conception with donor

Primipaternity after 38 years old or before 20 years old

Exclusion Criteria:

Multiple pregnancy

Pregnancy requiring termination

Unability to understand the study

Thrombophilia

treatment with heparin

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01348711